Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Issued (2021 - 2025)

Rani Therapeutics Holdings (RANI) has 5 years of Shares Issued data on record, last reported at -$3.9 million in Q3 2025.

  • For Q3 2025, Shares Issued changed N/A year-over-year to -$3.9 million; the TTM value through Sep 2025 reached $51000.0, up 163.75%, while the annual FY2024 figure was $51000.0, N/A changed from the prior year.
  • Shares Issued reached -$3.9 million in Q3 2025 per RANI's latest filing, down from $3.9 million in the prior quarter.
  • Across five years, Shares Issued topped out at $73.6 million in Q4 2021 and bottomed at -$3.9 million in Q3 2025.
  • Average Shares Issued over 5 years is $5.3 million, with a median of $45500.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: plummeted 365.31% in 2023, then skyrocketed 3319.01% in 2025.
  • A 5-year view of Shares Issued shows it stood at $73.6 million in 2021, then crashed by 100.2% to -$148000.0 in 2022, then skyrocketed by 45.95% to -$80000.0 in 2023, then skyrocketed by 163.75% to $51000.0 in 2024, then plummeted by 7819.61% to -$3.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$3.9 million in Q3 2025, $3.9 million in Q2 2025, and $42000.0 in Q1 2025.